Phase II Study of Icotinib With Concurrent Radiotherapy in Elderly Patients With Esophageal Cancer
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
To investigate the efficacy and toxicity of EGFR tyrosine-kinase inhibitor (Icotinib) with
concurrent radiotherapy in older patients with esophageal cancer.